[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity

Rhea-AI Filing Summary

Judy D. Olian, a director of United Therapeutics Corporation (UTHR), reported the sale of 1,800 shares of the issuer's common stock on 09/19/2025 at a weighted-average price of $415.4266 per share. After the reported disposition, the reporting person beneficially owned 5,045 shares. The Form 4 lists the transaction code as S (sale) and notes the trades executed at prices ranging from $415.29 to $415.55, with the weighted-average price disclosed above. The filing is signed under power of attorney by John S. Hess, Jr.

Positive

• None.

Negative

• Director sale: Reporting person sold 1,800 shares on 09/19/2025, reducing beneficial ownership to 5,045 shares
• Insufficient context: Filing provides no explanation (e.g., 10b5-1 plan or personal reasons) for the sale

Insights

Corporate Governance Expert

TL;DR: Director Judy Olian sold a small block of UTHR stock; filing discloses weighted-average price and post-sale ownership.

The Form 4 documents a reported sale of 1,800 common shares by a company director at a weighted-average price of $415.4266, leaving beneficial ownership of 5,045 shares. The filing includes an execution price range ($415.29–$415.55) and is signed under power of attorney, indicating administrative handling of the submission. For governance review, this is a routine disclosure of an insider sale with no additional context about reasons or any related agreements provided in the filing.

Securities Analyst

TL;DR: Insider sale recorded; amount and price are explicit but no context on timing or plan is disclosed.

From an investor-impact perspective, the sale of 1,800 shares at a weighted-average $415.4266 is a quantifiable change in insider holdings but is relatively small in absolute share count. The filing does not state a 10b5-1 plan or other arrangement, nor does it provide proceeds or tax/estate context. The disclosure meets Section 16 reporting requirements but contains no additional material information that would alone alter company valuation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Olian Judy D.

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		S		1,800	D	$415.4266(1)	5,045	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $415.29 to $415.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	09/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Judy D. Olian report on the Form 4 for UTHR?

The Form 4 reports a sale of 1,800 common shares on 09/19/2025 executed at a weighted-average price of $415.4266 per share.

How many UTHR shares does Judy D. Olian beneficially own after the reported transaction?

After the reported sale, the filing states she beneficially owns 5,045 shares.

What price range was disclosed for the trades in the Form 4?

The filing notes trades executed at prices ranging from $415.29 to $415.55, with a weighted-average price of $415.4266.

Was the Form 4 signed by the reporting person?

The signature on the filing is by John S. Hess, Jr. under power of attorney, dated 09/19/2025.

Does the Form 4 state whether the sale was part of a Rule 10b5-1 trading plan?

No. The filing does not state that the transaction was made pursuant to a Rule 10b5-1 trading plan or similar arrangement.